🇺🇸 FDA
Pipeline program

ASP8951, Sodium Chloride 0.9% Intravenous Infusion BP

8951-CL-0301

Phase 3 small_molecule active

Quick answer

ASP8951, Sodium Chloride 0.9% Intravenous Infusion BP for Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma is a Phase 3 program (small_molecule) at Astellas Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Astellas Pharma GmbH
Indication
Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials